FTO O-GlcNAcylation Induces Inactive Form Pyrin Expression, Which Suppresses NLRP3 Inflammasome Activation During LPS Stimulation

Xiao-Lian Zhang,Lu Zhang,Min Liu,Yan Xie,Bi-Feng Yuan,Zhiyong Peng,Jun Xiong
DOI: https://doi.org/10.21203/rs.3.rs-5408730/v1
2024-01-01
Abstract:The fat mass and obesity-associated protein (FTO), as a key RNA N6-methyladenosine (m6A) demethylase, has been recently highlighted in modulating inflammatory response. However, the role and underlying mechanisms of FTO, especially FTO O-GlcNAcylation, in LPS-induced inflammasome remain elusive. Here we uncover that FTO undergoes O-GlcNAcylation specifically at the Ser95 site. LPS-enhanced O-GlcNAcylation of FTO promotes TRIM21-mediated FTO ubiquitination degradation, subsequently increasing m6A-modified Mefv (encoding Pyrin) expression in macrophages. LPS stimulation or FTO O-GlcNAcylation increases inactive form Pyrin expression and can not cause Pyrin-ASC-Casp1 inflammasome activation. The Pyrin competitively blocks NLRP3-ASC-Casp1 inflammasome assembly and activation through the Pyrin-PYD domain, reduces gasdermin D (GSDMD) pyroptosis and restrains TNF-α/IL-1β/IL-6 production. FTO O-GlcNAcylation-deficiency or Pyrin knockdown aggravates the S. Typhimurium or LPS-induced sepsis and dextran sulfate sodium (DSS)-induced inflammatory bowel diseases (IBD). Our findings clarify that there is a regulatory network among protein O-GlcNAcylation, m6A modification, and inflammasome activation. FTO O-GlcNAcylation or Pyrin acts as a negative regulator of NLPR3-ASC-Casp1 inflammasome. The Pyrin plays an anti-inflammatory role in LPS-treated macrophages. Enhancement of FTO O-GlcNAcylation or inactive form Pyrin may offer a potential therapeutic strategy for combating endotoxin-induced NLRP3-mediated inflammatory responses and sepsis.
What problem does this paper attempt to address?